Tuesday September 25, 2:01 am Eastern Time
Press Release
SOURCE: Hypertension Diagnostics, Inc.
Makefield Securities Corporation Initiates Equity Research Coverage Of Hypertension Diagnostics
ST. PAUL, Minn., Sept. 25 /PRNewswire/ --
Hypertension Diagnostics, Inc. (Nasdaq: HDII - news) announced today that Makefield Securities Corporation initiated equity research coverage of HDI with a speculative buy rating and with a $11.50 twelve month price target. <>
Brad C. Dunlap and Gerald N. Kieft, analysts for Makefield Securities Corporation and authors of the report, commented, ``We are excited about HDI's transition from a development stage company into an operating company. Any reasonable success in the commercial launch of the CVProfilor® DO-2020 System should capture the attention of the investment community.''
Makefield Securities Corporation, founded in 1984, is a Florida-based broker/dealer established to provide institutional clearing and retail brokerage services for sophisticated investors.
HDI did not prepare this research analyst report. HDI does not approve or disapprove of the contents of this report. Further, the report may not be complete or accurate, and, therefore, investors should not rely on statements contained in it. Investors should make their own investigation of HDI's prospects before determining whether to purchase HDI securities.
<abridged>
biz.yahoo.com |
